0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > LOXL2

LOXL2

Brief Information

Name:Lysyl oxidase homolog 2
Target Synonym:EC 1.4.3,EC:1.4.3.13,WS9-14,LOR2,LOR,Lysyl oxidase-like protein 2,Lysyl oxidase homolog 2,LOXL2,Lysyl Oxidase Like 2,Lysyl Oxidase-Related Protein WS9-14,Lysyl Oxidase-Related Protein 2,Lysyl Oxidase-Like 2 Delta E13,Lysyl Oxidase-Like 2 Protein,Lysyl Oxi
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:3
Lastest Research Phase:Phase 2 Clinical

Product ListCompare or Buy

Synonym Name

Lysyl oxidase homolog 2,LOXL2

Background

Lysyl oxidase homolog 2 is also known as LOXL2, Lysyl oxidase-like protein 2, which is expressed in many tissues, highest expression in reproductive tissues, placenta, uterus and prostate, Up-regulated in a number of cancers cells and tissues. LOXL2 mediates the post-translational oxidative deamination of lysine residues on target proteins leading to the formation of deaminated lysine (allysine). When secreted in extracellular matrix, promotes cross-linking of extracellular matrix proteins by mediating oxidative deamination of peptidyl lysine residues in precursors to fibrous collagen and elastin. LOXL2 acts as a regulator of sprouting angiogenesis, probably via collagen IV scaffolding. When nuclear, acts as a transcription corepressor and specifically mediates deamination of trimethylated 'Lys-4' of histone H3 (H3K4me3), a specific tag for epigenetic transcriptional activation. LOXL2 acts as a regulator of chondrocyte differentiation, probably by regulating expression of factors that control chondrocyte differentiation.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
PAT-1251 PAT-1251 Phase 1 Clinical Pharmakea Therapeutics Idiopathic Pulmonary Fibrosis Details
PXS-5382 PXS-5382; PXS-5382A Phase 1 Clinical Pharmaxis Non-alcoholic Fatty Liver Disease; Idiopathic Pulmonary Fibrosis; Renal fibrosis Details
PXS-5338 PXS-5338 Phase 1 Clinical Pharmaxis Non-alcoholic Fatty Liver Disease; Liver Cirrhosis; Renal fibrosis; Pulmonary Fibrosis Details
GB-2064 GB-2064 Phase 2 Clinical Galecto Biotech Primary Myelofibrosis Details

This web search service is supported by Google Inc.

totop